
Opinion|Videos|July 12, 2024
Impact of Emerging Therapies on Outcomes for EGFR-Mutated NSCLC
Alan Chin, PharmD, BCOP, examines the PALOMA-3 trial's influence on the treatment of EGFR-mutated metastatic NSCLC and explores the evolving role of antibody-drug conjugates (ADCs) in the therapeutic landscape of EGFR-mutated NSCLC.
Advertisement
Episodes in this series

- How might the advent of subcutaneous amivantamab, currently being studied in the
PALOMA-3 trial, impact the treatment of EGFR-mutated metastatic NSCLC? What opportunities or challenges might this impose? - How do you see the role of antibody-drug conjugates (ADCs) evolving in the treatment landscape of EGFR-mutated NSCLC, and are there any in the pipeline that you are particularly excited about?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Men Face Higher Odds of Later-Stage Diagnosis Across 20 Cancer Types
2
Investigational mRNA Flu Vaccine Broadens Antibody Defenses, Sustains Immune "Training Hub" Longer Than Standard Shot
3
FDA Approves Enlicitide, the First Oral PCSK9 Inhibitor for High Cholesterol
4
FDA Accepts NDA for AD109 to Treat of Adults With Obstructive Sleep Apnea
5






































































































